Clinical and Pre-Clinical Data on the Novel Barriolide, EP395 (glasmacinal), Published in Three Articles in
REYKJAVIK, Iceland--(BUSINESS WIRE)--EpiEndo Pharmaceuticals ('EpiEndo' or the 'Company'), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory drugs which enhance the host defence response to inhaled pathogens, has had three articles published in peer-reviewed journal, Pulmonary Pharmacology and Therapeutics.
These publications describe the potential for EpiEndo's lead asset EP395, also known as 'glasmacinal', to be of therapeutic benefit in the treatment of COPD and support its continued clinical development. The article 'Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial' reports that EP395 enhances the host defence response to inhaled LPS whilst reducing pro-inflammatory mediators. The paper was co-authored with investigators from Fraunhofer Institute for Toxicology and Experimental Medicine who conducted the study.
The second article, 'Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation' describes preclinical data that demonstrate EP395 has comparable inhibitory effects on acute neutrophilic airway inflammation to azithromycin, which is used chronically off-label for its immunomodulatory properties to reduce COPD exacerbations.
Finally, 'A novel macrolide, EP395, with reduced antibacterial activity and an enhancing effect on respiratory epithelial barrier ' reports that EP395 has negligible antibiotic activity and enhances the barrier function of the respiratory epithelium.
Maria Bech, CEO of EpiEndo Pharmaceticals commented:
'It is great to see the publication of this clinical and pre-clinical research in a peer-reviewed journal, highlighting the efficacy we are seeing with glasmacinal in neutrophilic inflammation.
'The anti-inflammatory effects of glasmacinal are comparable to those seen with azithromycin preclinically, but without anti-microbial activity. The clinical LPS study shows that EP395 enhances the host defence response to inhaled challenge, supporting our hypothesis that glasmacinal could be effective in reducing exacerbations in COPD but without developing anti-microbial resistance.
'We continue to develop glasmacinal as a potential new oral treatment option for COPD patients, aiming to bring additional therapeutic options to patients with chronic respiratory diseases.'
Professor Clive Page, Emeritus Professor of Pharmacology, King's College London and Chairman of EpiEndo Pharmaceutical's Scientific Advisory Board added:
'These exciting new data demonstrate glasmacinal's effect on neutrophilic inflammation both in a clinical study and in established non-clinical models of airways disease. These novel findings, coupled with data presented at ERS in 2024 on EP395's anti-inflammatory effect on eosinophilic inflammation (caused by allergens), demonstrate the broad anti-inflammatory activity of this drug that has the potential to provide a novel, groundbreaking approach to treat patients with COPD, irrespective of their type of inflammation.'
About EpiEndo Pharmaceuticals (www.epiendo.com)
EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to chronic respiratory diseases that focuses on the role of epithelial function in various inflammatory disorders.
EpiEndo's new class of orally available macrolides, with reduced antimicrobial resistance (AMR) potential, known as 'Barriolides™', show promise as first-in-class therapeutics for chronic respiratory diseases as well as other inflammatory indications. EpiEndo's lead asset, glasmacinal, was the first Barriolide™ to enter clinical trials, for chronic obstructive pulmonary disease (COPD).
Glasmacinal aims to be a first on-market oral treatment which is anti-inflammatory and enhances the host defense response to inhaled pathogens such as viruses, bacteria & pollution. Therefore, glasmacinal has the potential to become an impactful treatment in reducing exacerbations in patients with COPD.
According to the WHO, COPD is the third leading cause of death globally, and the global economic burden of COPD is projected to cost $4.8 trillion by 2030.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Genesis Therapeutics Appoints Aleksandra Faust as Chief Artificial Intelligence Officer
BURLINGAME, Calif.--(BUSINESS WIRE)-- Genesis Therapeutics, a company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for the treatment of severe diseases, today announced the appointment of Aleksandra Faust, Ph.D., as Chief AI Officer. Dr. Faust joins Genesis with more than 20 years of leadership experience in the AI and tech industries, developing machine learning (ML) for complex systems such as robotics and autonomous vehicles. She most recently served as Director of Research at Google DeepMind, overseeing foundational model learning research and contributing to Gemini and to generalist web agents, among many other key innovations in her tenure. In her previous roles, she co-founded reinforcement learning research at Google Brain, founded task and motion planning research in Robotics at Google, led machine learning for self-driving car planning and controls at Waymo, and was a principal investigator at Sandia National Laboratories. 'We are excited to welcome Aleksandra to our world-class team of scientists, engineers and innovators,' said Evan Feinberg, Ph.D., founder and CEO of Genesis. 'As an established industry leader and pioneer in fundamental AI research across multiple complex domains, Aleksandra will play an instrumental role in elevating our GEMS platform's suite of generative and predictive AI technologies.' Dr. Faust earned a Ph.D. and a Master's degree in Computer Science from the University of New Mexico, and the University of Illinois at Urbana-Champaign, respectively. She has co-authored over 60 publications, the high impact of which is reflected in her h-index of 40, and her research has been featured in The New York Times and Forbes. Dr. Faust has also been recognized with numerous honors, including the IEEE Robotics and Automation Society Early Career Award and being named a Distinguished Alumna by the University of New Mexico School of Engineering. 'I am thrilled to join Genesis in its mission to usher in a new era of drug discovery with AI,' said Dr. Faust. 'The company's GEMS platform exemplifies how advanced machine learning can be synthesized with physics to enable the discovery of novel small molecule compounds that could produce breakthrough medicines for patients. I look forward to working with the talented Genesis team to push the boundaries of what is possible.' About Genesis Therapeutics Genesis Therapeutics, Inc. is an AI-focused biotechnology company leveraging its generative and predictive AI platform, GEMS (Genesis Exploration of Molecular Space), for small molecule drug discovery. GEMS integrates proprietary AI methods, including language models, diffusion models and physical simulation, to generate and optimize molecules for complex targets. Genesis has raised over $300 million from leading life science, tech, and AI-focused investors, and is building a therapeutics pipeline for a variety of high-impact targets. Genesis is headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego. For more information on Genesis, please visit the company's website at
Time Magazine
an hour ago
- Time Magazine
Can Air Conditioning Make You Sick?
At the height of the tuberculosis epidemic in the 19th century, doctors began advising people to venture outside to escape the ' bad air ' in their homes. In the 1960s, by contrast, AC became widespread in the U.S., increasing the appeal of staying inside. These days, many of us—the so-called ' indoor generation '—spend summer mostly inside, relying on AC to beat the heat. This technology saves lives; our sealed, climate-controlled spaces keep us healthy during dangerous heat waves. AC also helps many people avoid pollution outside. But did the 19th century physicians have a point about the downsides of stale indoor air? It depends. 'Multiple studies show that spending too much time in air-conditioned rooms can lead to more respiratory symptoms,' says Dr. William Checkley, a pulmonary and critical care physician and professor of medicine at Johns Hopkins School of Medicine. Here are the benefits, risks, and simple ways to make AC healthier this summer. The many benefits of AC AC is key to getting through summertime without a heat-related illness—or worse. 'The statistics on deaths from extreme heat are shocking, especially for the elderly and immunocompromised,' says Jeffrey Siegel, professor of civil engineering at the University of Toronto. From 1999 to 2023, heat-related deaths in the U.S. doubled. AC's benefits go beyond its cooling effect. A well-working AC system filters the air to reduce intake of dust, pollen, and airborne pathogens, Checkley says. AC is also critical in areas with pollution. Its filters can cleanse the air of particulate matter 2.5, a toxin shed in vehicle exhaust, industrial activity, and wildfires. Research shows that PM2.5 enters homes and contributes to heart and lung disease—but these effects aren't as severe in places with more AC use. 'Every time the AC system operates, it's pulling some particles out of the air,' says Brent Stephens, professor of civil, architectural, and environmental engineering at Illinois Institute of Technology. Cranking up the AC also makes the air less humid, reducing the dampness that contributes to bacterial growth, mold, and dust mites, which can contribute to—or, in rare cases, even cause—conditions like pneumonia, asthma, and COPD. Too much of a good thing Now, some big caveats. If you overdo it with AC, the air becomes too dry. If you're inhaling a lot of dry air, the human body adds water vapor to the inhaled air to maintain your internal humidity level, Checkley says. When you exhale, that moist air leaves your body with every breath. Ultimately, this dries out your respiratory tract, Checkley explains. The airways become irritated and inflamed, causing coughs, sore throat, and nasal congestion—a condition known as ' sick building syndrome.' Another consequence of air that's too dry: the lungs' natural defenses to microbes weaken, increasing susceptibility to disease, especially among kids and the immunocompromised. Viruses may be more likely to circulate in drier conditions. Think of how often people get sick right after long trips inside a dry airplane. It's the same effect in people's homes or offices. This may seem like a no-win situation: dampness leads to mold and dustmites, and dryness leads to cold-like symptoms and disease. However, there's a sweet spot. 'The ideal humidity in a home is between 40% and 60%,' Checkley says. Bacteria and viruses thrive both below and above these thresholds. 'There are indoor air conditions we can't perceive, which can be good or bad for us—it's not all about comfort,' says Dr. Stephanie Taylor, a clinician and consultant on healthy indoor environments. So how do you keep your home in the optimal humidity zone? Checkley advises buying a thermostat with a humidity sensor, called a hygrometer, to track the level. Many are inexpensive yet accurate. If humidity drops below 40%, give the AC a rest. If humidity tops 60%, crank it back up. Maintain your unit The AC may also pose health risks if it's working sub-optimally, even if it's not outright broken. 'What really matters is the condition of your air conditioning,' Siegel says. Much of this comes down to homeowner fundamentals like remembering to change your AC filter. With an old dirty filter, the AC coil and ducts could become 'cesspools of mold, bacteria, and allergens,' Taylor explains—which tag along with the AC's airflow. Slide in new filters every 1-2 months during peak AC use. The cost of additional filters is worth keeping up your home's air quality, Checkley says. Look for filters with minimum efficiency reporting value (MERV) ratings of 11 or 13. They're effective at trapping dust, mold, and other particles. In addition, calendar a yearly visit from an HVAC specialist. 'People think of AC as this magic black box that makes cold,' Siegel says. 'We only think about servicing it when it's not making cold anymore.' Even if the cold magic still works, a specialist should occasionally inspect the coil and ducts to ensure they're clean. In addition to regular assessments, get one after any major leak or other moisture problem, which can result in a dirty coil, Siegel adds. You can also install a UV light in your AC system. This device emits radiation that damages the cells of microorganisms like bacteria and mold—keeping the coil and interior components clean. Quality varies; make sure to work with a reputable manufacturer and contractor, and choose a light with a safety certification from UL or ETL, two independent organizations that test and certify products like lights for safety. Lights without these certifications may generate harmful byproducts, Taylor notes. Proper AC maintenance will also amplify AC's benefits, like thinning out PM2.5 from the air. 'With a decent filter, you reduce exposure to a ton of things we know have very serious health effects,' Siegel says. For a window AC, don't move it straight from the closet to the window when summer starts. 'Open it up and clean it first,' Taylor says. Use air purifiers Although your AC can—if it's working on all cylinders—clean PM2.5 pollution from outdoor sources, it does not clean another type of toxin that originates inside the home: volatile organic compounds, or VOCs. If the AC is on constantly, and you rarely open windows, your air may be rife with these chemicals. Potentially harmful VOCs are emitted by many home products such as furniture, cleaning supplies, and air fresheners. They've been linked to headaches, throat irritation, hormone disruption and, with long-term exposure, chronic diseases. VOCs play a role in what experts increasingly view as a building's microbiome, Taylor says. Indoor spaces, just like the human body, harbor communities of bacteria, fungi, and other microbes. With optimal humidity and AC maintenance, your indoor microbiome supports healthier, more diverse microbes. But VOCs can suppress or kill these microbes and promote the growth of pathogenic strains and imbalanced communities. Counter toxic VOCs by occasionally turning off the AC and opening windows. Indoor air has 2 to 5 times more VOCs than outdoor air, Stephens says. Another strategy: buy a portable HEPA air purifier. The best versions have carbon filters with porous surfaces that trap the gas molecules of VOCs, taking them out of the air. Purifiers also help remove about 50% of PM2.5. Stephens has one purifier on each level of his townhome. He keeps the purifiers' fan speeds on low or medium constantly to filter the air without having to think about it—but changes the speed to high when there's pollution, such as during rush hour when PM2.5 comes from outside, or when he's cleaning with chemicals that produce VOCs inside. VOC levels may be higher if your home is tightly sealed, trapping the chemicals inside. 'Every home is an absolute unicorn,' Stephens says. A professional air sampling measures VOCs. A number of VOC monitors are also available for people to buy, but Stephens says these consumer-grade devices can't detect levels of specific VOCs, so they won't tell you the potential toxicity or health risk. However, he adds that low-cost monitors for particles like PM2.5 have become much more accurate in recent years. An even less expensive, relatively simple humidity monitor combined with good AC maintenance will help ensure that you stay both cool and healthy this summer.
Yahoo
2 hours ago
- Yahoo
EMD Serono Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025
Cohort B of the Phase 2 study indicates all doses of enpatoran were associated with higher BICLA response rates compared with placebo, though the primary endpoint of BICLA dose-response relationship at Week 24 was not met Data show encouraging efficacy in a large subgroup of SLE patients with active cutaneous manifestations at baseline, including improved response rates in key disease activity measurements There is a substantial unmet treatment need for the estimated 70-80% of SLE patients who experience active cutaneous manifestations, which can profoundly impact quality of life1 BOSTON, June 12, 2025--(BUSINESS WIRE)--Not intended for media outside the U.S. or Canada EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, a leading science and technology company, today announced the presentation of detailed results from Cohort B of the global Phase 2 WILLOW study (NCT05162586) evaluating enpatoran, an investigational, oral, novel TLR7/8 inhibitor in systemic lupus erythematosus (SLE). Although it did not meet the primary endpoint of dose-response relationship, when compared to placebo, enpatoran demonstrated improvements in measures of both systemic and cutaneous disease activity in prespecified SLE subpopulations despite standard of care (SoC), including those with active cutaneous manifestations at baseline [(CLASI-A) ≥8], and was overall well tolerated. These findings will be presented in a late-breaking oral presentation at the 2025 European Congress of Rheumatology (EULAR) in Barcelona (Abstract # LB0004). "Analyses of Cohort B contribute to our understanding of enpatoran's potential to address the critical unmet needs for patients living with lupus, including those experiencing significant skin manifestations. These manifestations are often part of the systemic activity or flare, which can be painful and have a considerable impact on quality of life," said principal investigator Prof. Eric Morand, from Monash University and Monash Health. "The improvements observed in key disease measures represent a meaningful advancement in our ongoing investigation of the TLR7/8 inhibition approach for patients insufficiently managed by current therapies." WILLOW is a global, multicenter, randomized, placebo-controlled Phase 2 study evaluating three doses of oral enpatoran taken twice daily (25 mg, 50 mg and 100 mg) versus placebo plus SoC over 24 weeks. The study features a unique design across two lupus cohorts, including both patients with active SLE and cutaneous lupus erythematosus (CLE). Cohort B of the study was designed to evaluate the dose-response relationship of enpatoran in reducing disease activity, based on the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) response rate at Week 24 and enrolled SLE patients who had moderate or severe active disease despite SoC. Cohort B showed positive results in secondary and exploratory endpoints and within prespecified patient subpopulations. In patients with active skin disease (CLASI-A ≥8), BICLA response rates were up to 58.6% while placebo response rates were 31.7%, and up to 60.5% of patients receiving enpatoran showed a CLASI-70 response, compared with 26.8% for placebo, at Week 24. In addition, the subgroups of patients with high corticosteroid (prednisone-equivalent ≥10 mg/day) use and those with high interferon gene signature (IFN-GS) at baseline also showed higher and relevant BICLA response rates for enpatoran compared to placebo. As presented earlier this year at LUPUS 2025, Cohort A analyses from the WILLOW study showed clinically meaningful improvement in disease activity in patients with CLE and mild SLE with active lupus rash at Weeks 16 and 24. Overall, for skin-related signs and symptoms, comparable improvements were observed in Cohort B relative to Cohort A, reinforcing the potential efficacy of enpatoran in patients with cutaneous manifestations of lupus erythematosus with or without systemic disease. "The efficacy and tolerability results from Cohort B, particularly among those with active skin involvement—a manifestation that affects most lupus patients—are consistent with our observations from Cohort A. The lupus rash is not only a visible symptom but is also closely linked to the underlying systemic activity of lupus," said Jan Klatt, Head of Development Unit Neurology & Immunology for the Healthcare business of Merck KGaA, Darmstadt, Germany. "We are set to initiate regulatory discussions with key health authorities to determine the most effective pathway for bringing enpatoran to patients." Enpatoran was well-tolerated and exhibited a manageable safety profile consistent with previous studies, with no new safety signals identified. Rates of treatment-emergent adverse events (TEAEs) were comparable between all enpatoran arms and placebo, ranging from 60.6% to 64.2%, and the most frequently reported TEAEs were infections and infestations. These results further support the anticipated favorable safety profile of enpatoran. About Enpatoran Enpatoran is a selective Toll-like receptor (TLR)7/8 inhibitor under investigation for the treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). By inhibiting TLR7/8 activation, enpatoran may help reduce pro-inflammatory cytokines and autoantibody production, potentially addressing underlying mechanisms of chronic inflammation and disease progression in lupus. With its novel proposed mechanism of action and oral administration, enpatoran has the potential to be a first-in-class treatment for patients across lupus conditions. Enpatoran is currently under clinical investigation and is not approved for any use anywhere in the world. About the Phase 2 WILLOW Clinical Study WILLOW (NCT05162586) is a randomized, double-blind, placebo-controlled Phase 2 proof of concept and dose-finding study designed to evaluate the efficacy and safety of enpatoran in patients with systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). The study incorporates a basket design, including two cohorts – Cohort A including patients with CLE or SLE with active lupus rash and Cohort B including patients with active SLE. The WILLOW study aims to advance the understanding of enpatoran's therapeutic potential and to help address significant unmet needs in lupus treatment. About Lupus Erythematosus Lupus erythematosus is a chronic autoimmune disease that can affect various parts of the body, including the skin, joints, kidneys and other organs. It occurs when the immune system mistakenly attacks healthy tissues, leading to inflammation, pain and potential organ damage. There are multiple types of lupus, with systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) being two primary forms. Symptoms can range from mild to life-threatening, often including fatigue, joint pain, rashes and organ involvement. Lupus disproportionately impacts women and people of color, and despite available treatments, many patients experience unmet needs due to limited efficacy or side effects. EMD Serono in Neurology and Immunology EMD Serono has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company's current MS portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine) tablets. EMD Serono aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to EMD Serono's commitment to MS, the company also has a pipeline focusing on discovering new therapies that have potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and generalized myasthenia gravis (gMG). About EMD Serono, Inc. EMD Serono - the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada - aspires to create, improve and prolong life for people living with difficult-to-treat conditions like infertility, multiple sclerosis and cancer. The business is imagining the future of healthcare by working to translate the discovery of molecules into potentially meaningful outcomes for people with serious unmet medical needs. EMD Serono's global roots go back more than 350 years with Merck KGaA, Darmstadt, Germany. Today, the business has approximately 1,050 employees around the country with commercial, clinical and research operations in Massachusetts. About Merck KGaA, Darmstadt, Germany Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries. The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. 1 Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Manifestations of systemic lupus erythematosus. Maedica (Bucur). 2011 Oct;6(4):330-6. PMID: 22879850; PMCID: PMC3391953. View source version on Contacts Media Relations Phone: +1 781 427 1892 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
